Evaluation of hyperkalemia associated with intravenous co-trimoxazole in hospitalized patients in Oman
Main Article Content
Keywords
co-trimoxazole, intravenous, hyperkalemia
Abstract
Co-trimoxazole is a combination of two antimicrobial drugs, (trimethoprim and sulfamethoxazole), that are used to treat a wide variety of infections such as urinary tract infection, pneumocystis pneumonia and traveler’s diarrhea. Hyperkalemia is a life-threatening electrolyte disturbance. Objectives: This study aimed to determine the incidence of hyperkalemia and its risk factors among hospitalized patients receiving intravenous co-trimoxazole at Sultan Qaboos University Hospital (SQUH) in Muscat, Oman. Methods: This retrospective observational study included patients that were prescribed intravenous co-trimoxazole and identified using a computerized pharmacy system between January 2010 and December 2020. Patients’ demographic and clinical characteristics were retrieved from their electronic medical records. The data were analyzed using descriptive and inferential statistical tests. Results: A total of 420 patients participated in this study. The median age of the patients was 51 (35-65) years and 55.5% were male. Hyperkalemia associated with co-trimoxazole was observed in (40.2%) of the patients. Around (44.2%) of patients who experienced hyperkalemia received a high dose of co-trimoxazole (15-20 mg/kg). Hyperkalemia occurred after the 5th day of co-trimoxazole treatment. Logistic regression analysis showed no relationship between hyperkalemia and age (adjusted odds ratio (AOR) 1.054, p=0.84), sex (AOR 1.167; p=0.471), dose (AOR 0.779; p=0.251), or use of concomitant medications (angiotensin-converting inhibitors, AOR 1.054, p=0.84; angiotensin receptor blockers, AOR 0.564; p=0.734; β-blockers, AOR 0.986; p=0.963; potassium supplements, AOR 0.59; p=0.175; nonsteroidal anti-inflammatory drugs, AOR 0.842, p=0.684; spironolactone AOR 0.748, p=0.629; heparin AOR 0.822, p=0.382; calcineurin inhibitor, AOR 1.537, p=0.406). Conclusion: Co-trimoxazole use was associated with a high incidence of hyperkalemia in this group of patients. No association between hyperkalemia and risk factors was observed. Serum potassium levels should be closely monitored, especially in the first week of co-trimoxazole treatment, to prevent the incidence of hyperkalemia, and clinical staff should adhere to serum monitoring guidelines.
References
2. McIsaac WJ, Prakash P, Ross S. The management of acute uncomplicated cystitis in adult women by family physicians inn Canada. Can J Infect Dis Med Microbiol. 2008;19(4):287. https://doi.org/10.1155/2008/404939
3. Hicks LA, Taylor TH, Hunkler RJ. U.S outpatient antibiotic prescribing. N Engl J Med. 2013;368(15):1461-2. https://doi. org/10.1056/nejmc1212055
4. Burchall, J.J. Mechanism of action of trimethoprim-sulfamethoxazole. J Infect Dis 1973, 128, S437-41. https://doi.org/10.1093/ infdis/128.supplement_3.s437
5. Smith CL, Powell KR. Review of the Sulfonamides and Trimethoprim. Pediatr Rev. 2000;21(11):368-71.
6. Stevens RC, Laizure SC, Williams CL, Stein DS. Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. Antimicrob Agents Chemother. 1991;35(9):1884. https://doi. org/10.1128/aac.35.9.1884
7. Masters PA, O’Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-Sulfamethoxazole Revisited. Arch Intern Med. 2003;163(4):402-10. https://doi.org/10.1001/archinte.163.4.402
8. Rubin RH, Swartz MN. Trimethoprim-sulfamethoxazole. N Engl J Med. 1980;303(8):426-32. https://doi.org/10.1056/nejm198008213030804
9. Lawson DH, Jick H. Adverse reactions to co-trimoxazole in hospitalized medical patients. Am J Med Sci.1978;275(1):53-7. https://doi.org/10.1097/00000441-197801000-00005
10. Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann pharmacother. 2013;47(12):1618-26. https://doi.org/10.1177/1060028013509973
11. Joyce H, Hollander-Rodriguez C, Calvert JF. Hyperkalemia. Am Fam Physician. 2006;73(2):283-90.
12. Lyons CJ, Burgess MJ, Abildskov JA. Effects of acute hyperkalemia on cardiac excitability. Am Heart J. 1977; 94(6): 755-63.https://doi.org/10.1016/s0002-8703(77)80217-2
13. Collins AJ, Pitt B, Reaven N, Funk S, Mcgaughey K, Wilson D, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol. 2017;46(3):213-21. https:// doi.org/10.1159/000479802
14. Palmer BF, Clegg DJ. Hyperkalemia across the Continuum of Kidney Function. Clin J Am Soc Nephrol. 2018;13(1):155. https://doi.org/10.2215/cjn.09340817
15. Palmer BF,Clegg DJ. Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019. Am J Kidney Dis. 2019;74(5):682-95. https: https://doi.org/10.1053/j.ajkd.2019.03.427
16. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585-92. https://doi.org/10.1056/nejmra035279
17. Plantaz MMEA, Veldman BAJ, Esselink AC, Fleuren HWHA, Kramers C. Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients. Int J Clin Pharm. 2020;42(3):965-71. https://doi.org/10.1007/s11096-020-01039-8
18. Simon LV, Hashmi MF, Farrell MW. Hyperkalemia. Urology at a Glance. 2021;93-95. https://www.ncbi.nlm.nih.gov/books/ NBK470284/
19. Mengi T, Ozkok H, Comert B. Associated with Trimethoprim-Sulfamethoxazole in the Intensive Care Unit. J Crit Intensive Care. 2021;12:27-31.
20. Adawi RMA, Albu-Mahmood Z, Abdelgelil M, Abdelaziz H, Stewart D, Awaisu A. Incidence of Co-Trimoxazole-Induced Hyperkalemia in a Tertiary Care Hospital. Risk Manag. Healthc. Policy 2021;14:519-25. https://doi.org/10.2147/rmhp.s283471
21. Caulder CR, Kocherla CS, Qureshi ZP, Magagnoli J, Bookstaver PB. Dose-Dependent Hyperkalemia Among Hospitalized, HIV-Infected Patients Receiving Sulfamethoxazole/Trimethoprim. Ann pharmacother. 2020;54(9):852-7. https://doi.org/10.1177/1060028020909539
22. Mori H, Kuroda Y, Imamura S, Toyoda A, Yoshida I, Kawakami M, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. Internal medicine (Tokyo, Japan). 2003;42(8):665-9. https://doi.org/10.2169/internalmedicine.42.665
23. Higashioka K, Niiro H, Yoshida K, Oryoji K, Kamada K, Mizuki S, et al. Renal Insufficiency in Concert with Renin-angiotensinaldosterone Inhibition Is a Major Risk Factor for Hyperkalemia Associated with Low-dose Trimethoprim-sulfamethoxazole in Adults. Internal medicine (Tokyo, Japan). 2016;55(5):467-71. https://doi.org/10.2169/internalmedicine.55.5697
24. Weir MA, Juurlink DN, Gomes T, Mamdani M, Hackam DG, Jain AK, et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol. 2010;5(9):1544-51. https://doi.org/10.2215/cjn.01970310
25. Cremades A, Vicente-Ortega V, Peñafiel R. Influence of murine renal sexual dimorphism on amiloride-induced hyperkalemia. Nephron Physiol. 2003;95(3):57-66. https://doi.org/10.1159/000074331
26. Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Am J Nephrol. 1999;19(3):389-94. https://doi.org/10.1159/000013483
27. Kowalski SR, Tan MF. Plasma Potassium Concentration Changes Associated with Trimethoprim used for Urinary Tract Infections. J Pharm Pract. 2015;40(3):180-3. https://doi.org/10.1002/j.2055-2335.2010.tb00534.x
28. Mengi T, Ozkok H, Comert B. Associated with Trimethoprim-Sulfamethoxazole in the Intensive Care Unit. J Crit Intensive Care.2021;12:27-31.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.